Immune checkpoint inhibitors (ICIs), particularly those targeting programmed death 1 (PD-1), produce durable responses and enhance anti-tumor effects in a large number of patients with non-small-cell lung cancer. The gene discussed is PDCD1; the disease is neoplasm.